An Open-label Pilot Multicenter Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms

Administered By

Awarded By

Contributors

Start/End

  • August 12, 2020 - August 14, 2025